Comparing radiofrequency and cryoablation techniques for treating atrial fibrillation
Comparative Analysis of Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium in Patients With Persistent Atrial Fibrillation
This study is testing whether radiofrequency or cryoablation works better for treating people with persistent atrial fibrillation who haven't had success with other treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 158 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Bakulev Scientific Center of Cardiovascular Surgery Government |
| Locations | 1 site (Moscow) |
| Trial ID | NCT06253000 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of two interventional methods, radiofrequency ablation and cryoablation, in treating patients with persistent and long-term atrial fibrillation (AF). Atrial fibrillation is a significant risk factor for stroke, and this research seeks to identify predictors of recurrence in patients who have not responded to antiarrhythmic therapy. By comparing these two techniques, the study hopes to improve treatment outcomes for individuals suffering from AF and reduce the associated risks of stroke and disability.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with persistent or long-persisting atrial fibrillation that is resistant to antiarrhythmic therapy.
Not a fit: Patients with other significant cardiac pathologies, congenital heart defects, or those who are not compliant with follow-up visits may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients with atrial fibrillation, potentially reducing the risk of stroke and enhancing quality of life.
How similar studies have performed: Previous studies have shown promise in using both radiofrequency and cryoablation techniques for atrial fibrillation, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age over 18 years old; * Atrial fibrillation resistant to antiarrhythmic therapy; * Persistent and long-persisting form of atrial fibrillation; * The patient's consent to participate in the study. Exclusion Criteria: * Age under 18 and over 80 years old; * The presence of another cardiac pathology requiring surgical treatment; * Congenital heart defects; * Previous "open" cardiac surgery; * Bone marrow diseases; * Pathology of the blood coagulation system; * The left ventricular ejection fraction is less than 40%; * Moderate to severe renal insufficiency (creatinine clearance \<50 ml/min); * Drug-resistant hypertension (despite hypotensive therapy); * Organically altered mitral valve; * There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons; * The patient's participation in another clinical trial.
Where this trial is running
Moscow
- Bakulev National Medical Research Center for Cardiovascular Surgery — Moscow, Russia (Recruiting)
Study contacts
- Principal investigator: Andrey Filatov — Bakulev Scientific Center for Cardiovascular Surgery
- Study coordinator: Andrey Filatov
- Email: agfilatov@bakulev.ru
- Phone: +7(495) 414-77-02
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.